Interleukin-18, interferon-γ, IP-10, and Mig expression in Epstein- Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease

American Journal of Pathology

Volumn 155, Issue 1, 1999, Pages 257-265

  Setsuda, Joyce ^a   Teruya Feldstein, Julie ^a   Harris, Nancy L ^b   Ferry, Judith A ^b   Sorbara, Lynn ^a   Gupta, Ghanshyam ^c   Jaffe, Elaine S ^a   Tosato, Giovanna ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 18; RANTES;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INFECTIOUS MONONUCLEOSIS; INTERFERON INDUCTION; INTERFERON PRODUCTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDIATOR RELEASE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033052486     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65119-X     Document Type: Article

References (49)

1. Miller G: Epstein-Barr virus, biology, pathogenesis, and medical aspects. Epstein-Barr Virus, Biology, Pathogenesis, and Medical Aspects. B Fields, D Knipe, eds. New York, Raven Press, 1990, pp 1921-1958
2. Straus SE, Cohen JI, Tosato G, Meier J: NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993, 118:45-58
3. Rickinson AB, Lee SP, Steven NM: Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996, 8:492-497
4. Masucci MG, Ernberg I: Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol 1994, 2:125-130
5. Nalesnik MA, Jaffe R, Starzl TE, Demetris TJ, Porter K, Burnham KA, Makowka L, Ho M, Locker J: The pathology of posttransplant lympho-proliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988, 133:173-192
6. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw Jr, BW, Hardesty, RL, Atchinson RW, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587
7. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation [see comments]. N Engl J Med 1994, 330:1185-1191
8. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555
9. Heslop HE, Rooney CM: Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997, 157:217-222
10. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994, 97:14-24
11. Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE: Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996, 119:544-551
12. Chen JM, Barr ML, Chadburn A, Frizzera G, Schenkel FA, Sciacca RR, Reison DS, Addonizio LJ, Rose EA, Knowles DM, Michler RE: Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993, 56:527-538
13. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients [see comments], N Engl J Med 1990, 323:1723-1728
14. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA: Post-transplant lymphoproliferative disorder in renal allograft recipients: clinical experience and risk factor analysis in a single center. Transplantation 1993, 56:88-96
15. Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M: Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegabvirus disease. J Infect Dis 1997, 176:1462-1467
16. Wolf J, Draube A, Bohlen H, Jox A, Mucke S, Pawlita P, Moller M, Diehl V: Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells. Int J Cancer 1995, 60:527-533
17. Tosato G, Sgadari C, Taga K, Jones KD, Pike SE, Rosenberg A, Sechler JM, Magrath IT, Love LA, Bhatia K: Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood 1994, 83:776-784
18. Sgadari C, Angiolillo AL, Cherney B-, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996, 93:13791-13796
19. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997, 89:2635-2643
20. Ferry JA, Jacobson JO, Conti D, Delmonico F, Harris NL: Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989, 2:583-592
21. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I: Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995, 103:748-755
22. Harris NL, Ferry JA, Swerdlow SH: Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology workshop. Semin Diagn Pathol 1997, 14:8-14
23. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko F, Raffeld M: Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996, 88:242-251
24. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, Longo DL, Tosato G: The role of Mig, the monokine induced by interferon-γ. and IP-10, the interferon-γ-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997, 90: 4099-4105
25. Segal GH, Jorgensen T, Scott M, Braylan RC: Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. Follicular lymphomas [see comments]. Hum Pathol 1994, 25:1276-1282
26. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G: Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/ IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992, 148:92-98
27. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M: Cloning of a new cytokine that induces IFN-γ production by T cells [see comments]. Nature 1995, 378:88-91
28. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M: Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996, 156:4274-4279
29. Moore KW. O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993, 11:165-190
30. Stuart AD, Stewart JP, Arrand JR, Mackett M: The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 1995, 11:1711-1719
31. Beatty PR, Krams SM, Martinez OM: Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines J Immunol 1997, 158:4045-4051
32. Taga H, Taga K, Wang F, Chretien J, Tosato G: Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. J Infect Dis 1995, 171:1347-1350
33. Birkeland SA, Bendtzen K: Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder [letter]. Transplantation 1996, 61:1425-1426
34. Raymond E, Tricottet V, Samuel D, Reynes M, Bismuth H, Missel JL: Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer 1995, 76:1344-1351
35. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603
36. Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K: Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997, 94:3948-3953
37. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997, 7:571-581
38. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production. Eur J Immunol 1996, 26:1647-1651
39. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Aral S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997, 43:361-367
40. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WMF: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998, 101:1441-1452
41. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M: CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629
42. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997, 61:246-257
43. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR: Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993, 268:5834-5839
44. Shin HS, Drysdale BE, Shin ML, Noble PW, Fisher Sn, Paznekas WA: Definition of a lipopolysaccharide-responsive element in the 5′-flanking regions of MuRantes and crg-2. Mol Cell Biol 1994, 14:2914-2925
45. Thomas LH, Friedland JS, Sharland M, Becker S: Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B α. J Immunol 1998, 161:1007-1016
46. Bacon KB, Premack BA, Gardner P, Schall TJ: Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995, 269: 1727-1730
47. Ault KA, Antin JH, Ginsburg D, Orkin SH. Rappeport JM, Keohan ML, Martin P, Smith BR: Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 1985, 161:1483-1502
48. Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P, Pecora A, Gillio A, Kernan NA, O'Reilly RJ: Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989, 73:1340-1350
49. Keever CA, Welte K, Small T, Levick J, Sullivan M, Hauch M, Evans RL, O'Reilly RJ: Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. Blood 1987, 70:1893-1903